These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 33925671)

  • 1. Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?
    Fanale D; Incorvaia L; Badalamenti G; De Luca I; Algeri L; Bonasera A; Corsini LR; Brando C; Russo A; Iovanna JL; Bazan V
    Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33925671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?
    Fanale D; Corsini LR; Brando C; Cutaia S; Di Donna MC; Filorizzo C; Lisanti MC; Randazzo U; Magrin L; Romano R; Bazan Russo TD; Olive D; Vieni S; Pantuso G; Chiantera V; Russo A; Bazan V; Iovanna JL
    Front Oncol; 2022; 12():946319. PubMed ID: 36212445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer.
    Fanale D; Brando C; Corsini LR; Cutaia S; Di Donna MC; Randazzo U; Filorizzo C; Lisanti C; Magrin L; Gurrera V; Romano R; Dimino A; Bazan Russo TD; Olive D; Vieni S; Pantuso G; Giordano A; Chiantera V; Russo A; Bazan V; Iovanna JL
    BMC Cancer; 2023 May; 23(1):437. PubMed ID: 37179293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions.
    Incorvaia L; Fanale D; Badalamenti G; Porta C; Olive D; De Luca I; Brando C; Rizzo M; Messina C; Rediti M; Russo A; Bazan V; Iovanna JL
    Oncoimmunology; 2020 Oct; 9(1):1832348. PubMed ID: 33178494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma.
    Bian B; Fanale D; Dusetti N; Roque J; Pastor S; Chretien AS; Incorvaia L; Russo A; Olive D; Iovanna J
    Oncoimmunology; 2019; 8(4):e1561120. PubMed ID: 30906655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay.
    Incorvaia L; Rinaldi G; Badalamenti G; Cucinella A; Brando C; Madonia G; Fiorino A; Pipitone A; Perez A; Li Pomi F; Galvano A; Gristina V; Barraco N; Bono M; Bazan Russo TD; Toia F; Cordova A; Fanale D; Russo A; Bazan V
    Ther Adv Med Oncol; 2023; 15():17588359231151845. PubMed ID: 36818688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic monitoring of serum soluble programmed cell death ligand 1 as a response predictor to chemotherapy in metastatic or recurrent gastrointestinal cancer.
    Sun J; Qiu MZ; Mei T; Gao Y; Chang B; Zhang Y; Wang FH; Li S
    Transl Cancer Res; 2020 Apr; 9(4):2434-2448. PubMed ID: 35117603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis.
    Scirocchi F; Strigari L; Di Filippo A; Napoletano C; Pace A; Rahimi H; Botticelli A; Rughetti A; Nuti M; Zizzari IG
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type and Gene Location of
    Incorvaia L; Fanale D; Vincenzi B; De Luca I; Bartolotta TV; Cannella R; Pantuso G; Cabibi D; Russo A; Bazan V; Badalamenti G
    Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33673554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
    Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
    [No Abstract]   [Full Text] [Related]  

  • 11. Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody.
    Murakami S; Shibaki R; Matsumoto Y; Yoshida T; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Ohe Y
    Thorac Cancer; 2020 Dec; 11(12):3585-3595. PubMed ID: 33108686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma.
    Montemagno C; Hagege A; Borchiellini D; Thamphya B; Rastoin O; Ambrosetti D; Iovanna J; Rioux-Leclercq N; Porta C; Negrier S; Ferrero JM; Chamorey E; Pagès G; Dufies M
    Oncoimmunology; 2020 Nov; 9(1):1846901. PubMed ID: 33299657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma.
    Larrinaga G; Solano-Iturri JD; Errarte P; Unda M; Loizaga-Iriarte A; Pérez-Fernández A; Echevarría E; Asumendi A; Manini C; Angulo JC; López JI
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33562338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Prognostic Value of Plasma Programmed Death Protein-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Patients with Gastrointestinal Stromal Tumor.
    Brinch CM; Hogdall E; Junker N; Moeller HJ; Sandfeld-Paulsen B; de Heer P; Penninga L; Rossen PB; Krarup-Hansen A; Aggerholm-Pedersen N
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
    Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis.
    Carosio R; Fontana V; Mastracci L; Ferro P; Grillo F; Banelli B; Canessa PA; Dessanti P; Vigani A; Morabito A; Pfeffer U; Poggi A; Roncella S; Pistillo MP
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):459-468. PubMed ID: 33216211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma.
    Wang L; Wang H; Chen H; Wang WD; Chen XQ; Geng QR; Xia ZJ; Lu Y
    Oncotarget; 2015 Dec; 6(38):41228-36. PubMed ID: 26515600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study.
    Tiako Meyo M; Jouinot A; Giroux-Leprieur E; Fabre E; Wislez M; Alifano M; Leroy K; Boudou-Rouquette P; Tlemsani C; Khoudour N; Arrondeau J; Thomas-Schoemann A; Blons H; Mansuet-Lupo A; Damotte D; Vidal M; Goldwasser F; Alexandre J; Blanchet B
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32085544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble PD-L1 as a diagnostic and prognostic biomarker in resectable gastric cancer patients.
    Chivu-Economescu M; Herlea V; Dima S; Sorop A; Pechianu C; Procop A; Kitahara S; Necula L; Matei L; Dragu D; Neagu AI; Bleotu C; Diaconu CC; Popescu I; Duda DG
    Gastric Cancer; 2023 Nov; 26(6):934-946. PubMed ID: 37668884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
    Okuma Y; Hosomi Y; Nakahara Y; Watanabe K; Sagawa Y; Homma S
    Lung Cancer; 2017 Feb; 104():1-6. PubMed ID: 28212990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.